A Phase 2/3, Randomized, Double-blind, Comparator- and Placebo-controlled Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TLC590 for Postsurgical Pain Management Following Inguinal Hernia Repair
Latest Information Update: 16 Apr 2024
At a glance
- Drugs Ropivacaine (Primary) ; Bupivacaine
- Indications Postoperative pain
- Focus Pharmacokinetics; Registrational
- Sponsors Taiwan Liposome Company; TLC Biopharmaceuticals
- 09 Apr 2024 Planned initiation date changed from 1 Nov 2023 to 1 Apr 2025.
- 21 Apr 2023 Planned End Date changed from 1 Dec 2024 to 1 Dec 2025.
- 21 Apr 2023 Planned primary completion date changed from 1 Dec 2024 to 1 Dec 2025.